Mavoglurant

Reference

1. ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  уреди
2. ^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1. 
3. ^ ^{а б} P. Cole (2012). „Mavoglurant”. Drugs of the Future. 37 (1): 7—12. doi:10.1358/dof.2012.37.1.1772147. 
4. ^ Levenga, J; Hayashi, S; De Vrij, FM; Koekkoek, SK; Van Der Linde, HC; Nieuwenhuizen, I; Song, C; Buijsen, RA; et al. (2011). „AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome”. Neurobiology of disease. 42 (3): 311—7. PMID 21316452. doi:10.1016/j.nbd.2011.01.022. CS1 одржавање: Експлицитна употреба et al. (веза)
5. ^ Jacquemont, S.; Curie, A.; Des Portes, V.; Torrioli, M. G.; Berry-Kravis, E.; Hagerman, R. J.; Ramos, F. J.; Cornish, K.; et al. (2011). „Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome is Associated with Differential Response to the mGluR5 Antagonist AFQ056”. Science Translational Medicine. 3 (64): 64ra1. PMID 21209411. doi:10.1126/scitranslmed.3001708. CS1 одржавање: Експлицитна употреба et al. (веза)
6. ^ „AFQ056 drug improves symptoms in Fragile X patients: Study”. news-medical.net. 9. 1. 2011. 

Spoljašnje veze